Presented by:

Madhav Paranjpe, DVM, MS, PhD, DACVP, FIATP
Director of Pathology at BioReliance

The rasH2 transgenic mouse supports faster and more accurate carcinogenicity studies, with 75% shorter timelines than conventional two-year rodent bioassays. Can this transgenic mouse tighten your drug development pipeline, while reducing false positives?

Carcinogenicity Testing Insights

1178-rash2-insight.jpg In this exclusive webinar, we will explore the historical control database of neoplastic and non-neoplastic lesions from dozens of rasH2 carcinogenicity studies, demonstrating an extremely low incidence of the spontaneous tumors and non-lethal legions which can confound two-year rodent carcinogenicity studies.
  • Low incidence of spontaneous tumors

  • No tumor drifts

  • Low incidence of lethal degenerative changes

  • 75% shorter carcinogenicity testing studies


Dr. Madhav Paranjpe Dr. Madhav Paranjpe, DVM, MS, PhD, DACVP, FIATP, is a Director of Pathology at BioReliance in Rockville, MD, USA. He is primarily involved in the evaluation of Dose Range Finding Studies and final six-month short term carcinogenicity studies.

Dr. Paranjpe has published twenty papers in peer-reviewed journals and presented several seminars on transgenic mice, particularly the Tg.rasH2. He received an Best Publication award in 2013 from ACT/IJT. Recently, in 2016, he received an award from the 2016 IQ Consortium and AAALAC International Global 3Rs Award for North America for his paper. “Regulatory Forum Opinion Piece*: Retrospective Evaluation of Doses in the 26-week Tg.rasH2 Mice Carcinogenicity Studies: Recommendation to Eliminate High Doses at Maximum Tolerated Dose (MTD) in Future Studies.”

View this exclusive webinar!

Watch Now!

© 2024 Taconic Biosciences, Inc. All rights reserved.

© 2024 Taconic Biosciences, Inc. All rights reserved.